Hybio Pharmaceutical Co., Ltd. (300199)の価格はいくらですか

Hybio Pharmaceutical Co., Ltd. (300199)の価格は$3.33です

Hybio Pharmaceutical Co., Ltd. (300199)の時価総額は何ですか

Hybio Pharmaceutical Co., Ltd. (300199)の時価総額は$2.95Bです

Hybio Pharmaceutical Co., Ltd.（300199）営業利益率

Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.

年	営業利益率	変化
提供された日付のデータは十分ではありません。

年

営業利益率

変化

提供された日付のデータは十分ではありません。

企業	営業利益率	営業利益率の差	国
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	-	DE
Merck KGaA MRK.DE	0.00%	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	-	JP
Galderma Group AG GALD.SW	0.00%	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	22.93%	-	IN

企業

営業利益率

営業利益率の差

国